1800-272-662
Shopping Cart 0
countryflagAU
Login

Hepion Pharmaceuticals Inc

Healthcare US HEPA

0.0632USD
-(-%)

Last update at 2025-09-11T19:17:00Z

Day Range

0.050.07
LowHigh

52 Week Range

1.0612.88
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap6.29M
  • Volume20005
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-37.15126M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-9.65

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -49.33506M -45.08390M -32.72217M -20.32335M -7.94602M
Minority interest - - - - -
Net income -48.92604M -42.20005M -32.72217M -20.35394M -7.03734M
Selling general administrative 9.62M 10.35M 10.01M 8.15M 4.59M
Selling and marketing expenses 0.07M - - - -
Gross profit -0.06713M -0.07746M -0.08607M -0.03451M -0.02674M
Reconciled depreciation 0.07M 0.08M 0.09M 0.03M 0.03M
Ebit -45.25795M -43.61780M -30.40331M -20.14607M -7.94974M
Ebitda -45.19082M -43.54034M -30.31724M -20.11156M -7.92300M
Depreciation and amortization 0.07M 0.08M 0.09M 0.03M 0.03M
Non operating income net other - - - - -
Operating income -45.25795M -45.48873M -30.40331M -20.14607M -7.77008M
Other operating expenses 45.26M 43.62M 30.40M 20.15M 7.77M
Interest expense 0.00946M 0.01M 0.00886M 0.03M 0.55M
Tax provision -2.88385M -2.88385M -0.00294M 0.03M -1.22732M
Interest income - - - - 0.18M
Net interest income -0.00957M -0.01016M -0.00886M -0.03123M -0.55500M
Extraordinary items - - - - -
Non recurring - 1.87M - - -
Other items - - - - -
Income tax expense -0.40902M -2.88385M 0.00886M 0.03M -0.90868M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 45.19M 43.62M 30.40M 20.15M 7.77M
Cost of revenue 0.07M 0.08M 0.09M 0.03M 0.03M
Total other income expense net -4.07711M -1.45593M -2.31000M -0.14605M 0.38M
Discontinued operations - - - - -
Net income from continuing ops -44.67789M -42.20005M -32.72217M -20.35394M -6.71870M
Net income applicable to common shares - -45.33755M -32.72217M -20.35922M -12.16165M
Preferred stock and other adjustments - 3.14M - 0.00529M -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 18.09M 60.24M 103.55M 48.65M 20.43M
Intangible assets - 3.19M 3.19M 3.19M 3.19M
Earning assets - - - - -
Other current assets 2.70M 5.31M 6.10M 1.91M 0.47M
Total liab 10.81M 10.39M 10.56M 8.12M 4.25M
Total stockholder equity 7.28M 49.86M 93.00M 40.52M 16.18M
Deferred long term liab - 0.41M - 3.19M 3.19M
Other current liab 0.39M 5.17M 2.99M 0.66M 0.49M
Common stock 0.00048M 0.00762M 0.00762M 0.00320M 0.00038M
Capital stock 1.70M 1.70M 1.71M 1.72M 1.72M
Retained earnings -224.62739M -175.70134M -133.50129M -104.10546M -83.18563M
Other liab - 2.50M 2.30M 2.99M 2.45M
Good will - 0.00000M 1.87M 1.87M 1.87M
Other assets - 0.43M 0.58M 4.03M 3.32M
Cash 14.79M 51.19M 91.35M 40.73M 13.92M
Cash and equivalents - - - - -
Total current liabilities 5.29M 7.89M 8.21M 4.66M 1.25M
Current deferred revenue 2.44M - 2.51M - -
Net debt -14.57686M -51.13547M -91.03198M -39.97467M -13.11552M
Short term debt 0.12M 0.05M 0.27M 0.28M 0.27M
Short long term debt - - - - -
Short long term debt total 0.21M 0.05M 0.32M 0.75M 0.81M
Other stockholder equity 230.29M 223.94M 224.79M 142.91M 97.65M
Property plant equipment - 0.08M 0.46M 0.66M 0.86M
Total current assets 17.49M 56.50M 97.45M 42.63M 14.39M
Long term investments - - - - -
Net tangible assets - 44.97M 86.23M 36.94M 12.60M
Short term investments - - - - -
Net receivables - - - - -
Long term debt - - - 0.18M -
Inventory - - - - -
Accounts payable 2.35M 2.67M 2.45M 3.72M 0.49M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.07878M -0.09017M - - -
Additional paid in capital - - - - -
Common stock total equity - 0.00762M - 0.00320M 0.00038M
Preferred stock total equity - 1.70M - 1.71M -
Retained earnings total equity - -175.70134M - -104.10546M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.30M 0.43M 0.58M 0.29M 0.13M
Deferred long term asset charges - - - - -
Non current assets total 0.61M 3.75M 6.10M 6.01M 6.04M
Capital lease obligations 0.21M 0.05M 0.32M 0.58M 0.81M
Long term debt total - - - 0.18M -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.03029M -0.01407M -0.13040M -0.08579M -0.05147M
Change to liabilities - 2.25M -1.06785M 3.04M -0.42436M
Total cashflows from investing activities - -0.01407M -0.13040M -0.08579M -0.05147M
Net borrowings - - -0.17658M 0.18M -1.11940M
Total cash from financing activities 4.49M -5.13750M 81.98M 43.05M 18.71M
Change to operating activities - 0.91M -4.49935M -1.41043M -0.33025M
Net income -48.92604M -42.20005M -32.72217M -20.35394M -6.71870M
Change in cash -36.40321M -40.15988M 50.62M 26.80M 11.09M
Begin period cash flow 51.19M 91.35M 40.73M 13.92M 2.83M
End period cash flow 14.79M 51.19M 91.35M 40.73M 13.92M
Total cash from operating activities -40.88888M -34.96117M -31.22448M -16.16520M -7.56506M
Issuance of capital stock 0.00000M 17.86M 82.15M 42.87M 17.74M
Depreciation 0.07M 0.08M 0.09M 0.03M 0.03M
Other cashflows from investing activities - 0.00227M - 0.00219M -
Dividends paid 0.00100M 0.00500M 0.01M 0.01000M 0.15M
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 0.00000M -21.00000M 0.18M 42.88M 0.15M
Other cashflows from financing activities 0.00100M -1.99500M -0.16559M 0.20M 13.39M
Change to netincome - 4.01M 6.98M 2.53M -0.60510M
Capital expenditures 0.01M 0.02M 0.13M 0.09M 0.05M
Change receivables - - - - -
Cash flows other operating - 0.91M - -1.41043M -
Exchange rate changes - - - - -
Cash and cash equivalents changes - -40.11274M - 26.80M -
Change in working capital 2.97M 3.15M -5.56720M 1.63M -0.75460M
Stock based compensation 1.34M 2.55M 4.67M 2.38M 0.07M
Other non cash items 4.07M 1.46M 2.31M 0.14M 0.16M
Free cash flow -40.90318M -34.97751M -31.35489M -16.25318M -7.61653M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
HEPA
Hepion Pharmaceuticals Inc		 - -% 0.06 - - - 0.68 0.15
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Hepion Pharmaceuticals Inc

399 Thornall Street, Edison, NJ, United States, 08837

Key Executives

Name Title Year Born
Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D. Pres, CEO & Director 1958
Mr. John T. Cavan Chief Financial Officer 1958
Dr. Todd M. Hobbs M.D. Chief Medical Officer 1969
Dr. Launa J. Aspeslet Ph.D. Chief Operating Officer NA
Dr. Daren Ure Ph.D. Chief Scientific Officer NA
Sharen Pyatetskaya Director of Investor Relations NA
Dr. Daniel J. Trepanier Ph.D. Sr. VP of Drug Devel. NA
Dr. Patrick R. Mayo Ph.D. Sr. VP of Clinical Pharmacology NA
Dr. John Z. Sullivan-Bolyai Part-Time Consultant 1948
Dr. Stephen A. Harrison M.D. Member of Scientific Advisory Board & Consultant Medical Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.